The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: A randomized, double-blind, placebo-controlled, clinical trial

Phytotherapy Research

Volumn 20, Issue 12, 2006, Pages 1036-1039

  Huseini, H Fallah ^a   Larijani, B ^b   Heshmat, R ^b   Fakhrzadeh, H ^b   Radjabipour, B ^b   Toliat, T ^c   Raza, Mohsin ^d  

^a AVICENNA RESEARCH INSTITUTE   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Antioxidant; Diabetes; Herbal medicine; Silymarin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PLACEBO; SILYBUM MARIANUM EXTRACT; SILYMARIN; TRIACYLGLYCEROL;

ADULT; ALLOPATHY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SILYBUM MARIANUM; TABLET FORMULATION;

BLOOD CHEMICAL ANALYSIS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MILK THISTLE; PHYTOTHERAPY; PLANT EXTRACTS; SEEDS;

SILYBUM MARIANUM;

EID: 33845618025     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.1988     Document Type: Article

References (23)

1. American Diabetes Association. 2003. Screening for type 2 diabetes. Diabetes Care 26(Suppl 1): 12-13.
2. Boden G. 1997. Role of fatty acids in the pathogenesis of insulin resistance in NIDDM. Diabetes 46: 3-10.
3. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
4. Evans JL, Goldfine. 2000. ID: alpha-lipoic acid: a multi-functional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther 2: 401-413.
5. Flora K, Hahn M, Rosen H, Benner K. 1998. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93: 139-143.
6. Jacob S, Lehmann R, Rett K, Häring HU. 2000. Oxidative stress and insulin action: a role for antioxidants. In Antioxidants in Diabetes Management, Packer L, Rösen P, Tritschler HJ, King GL (eds). Marcel Dekker: New York, 319-338.
7. Lirussi F, Beccarello A, Zanette G et al. 2002. Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabet Nutr Metab 15: 222-231.
8. Maddux BA, See W, Lawrence JC Jr, Goldfine AL Goldfine, ID, Evans JL. 2001. Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by micro molar concentrations of alpha-lipoic acid. Diabetes 50: 404-410.
9. McGarry JD. 2002. Banting Lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51: 7-18.
10. Packer L, Rosen P, Tritschler H, King GL, Azzi A (eds). 2000. Antioxidants and Diabetes Management. Marcel Dekker: New York.
11. Parish RC, Doering PL. 1986. Treatment of Amanita mushroom poisoning: a review. Veter Human Toxicol 28: 318-322.
12. Pepping J. 1999. Milk thistle: Silybum marianum. Am J Health Syst Pharm 56: 1195-1197.
13. Rudich A, Tirosh A, Potashnik R, Khamaisi M, Bashan N. 1999. Lipoic acid protects against oxidative stress induced impairment in insulin stimulation of protein kinase B and glucose transport in 3T3-L1 adiposities. Diabetologia 42: 949-957.
14. Skottova N, Krecman V, Simanek V. 1999. Activities of silymarin and its flavonolignans upon low density lipoprotein oxidizability in vitro. Phytother Res 13: 535-537.
15. Sonnenbichler J, Goldberg M, Hane L, Madubunyi I, Vogl S, Zetl I. 1986. Stimulatory effect of silibinin on DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malign cell lines. Biochem Pharmacol 35: 538-541.
16. Soto C, Mena R, Luna J et al. 2004. Silymarin induces recovery of pancreatic function after alloxan damage in rats. Life Sci 75: 2167-2180.
17. Soto CP, Perez BL, Favari LP, Reyes JL. 1998. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp Pharmacol Toxicol 119: 125-129.
18. Soto C, Recoba R, Barron H, Alvarez C, Favari L. 2003. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Physiol Toxicol Pharmacol 136: 205-212.
19. Tsuzura S, Ikeda Y, Suehiro T et al. 2004. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes. Metabolism 53: 297-302.
20. Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C, Zilli M. 1997. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 26: 871-879.
21. Velussi M, Cernigoi AM, Viezzoli L, Dapas F, Caffau C, Zilli M. 1993. Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin needs in cirrhotic diabetic patients. Curr Ther Res 53: 533-545.
22. Von Schonfeld J, Weisbrod B, Muller MK. 1997. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin toxicity. Cell Mol Life Sci CMLS 53: 917-920.
23. Zhang JQ, Mao XM, Zhou YP. 1993. Effects of silybin on red blood cell sorbitol and nerve conduction velocity in diabetic patients. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi 12: 725-726.